Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 176 In stock
USD 110 In stock
USD 170 In stock
USD 270 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
ATR [12]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM 1.8 μM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVeyMlUh|ryP MXGxMVQh\A>? NGXKOW1FVVOR MorE[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> NY\udpZ{OjV2OUCzPFM>
H1703 M1XERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu2ZXRwOi53IN88US=> MUSxMVQh\A>? NH7nUmhFVVOR M1S1VYVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv M2fY[|I2PDlyM{iz
HUVECs NGLrUnNEgXSxdH;4bYNqfHliQYPzZZk> M1SzW|ExOCCwTR?= M{fNNlI1KGh? MljrZZR1\W63YYTld{B1cGViYXLyc4difGm4ZTDl[oZm[3S|IH;mJINidHmlb4PpckBwdiCYUlmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> MljKNlU1PTBzOE[=
APRE-19 M2rkeWFxd3C2b4Ppd{BCe3OjeR?= M2\yUFUh|ryP M2LTd|I1KGh? M2\2SIFjd2yrc3jld{BHVFpvbXXkbYF1\WRicILvMZN2en[rdnHsM4FvfGlvYYDvdJRwe2m|IHHjeIl3cXS7 M{LmWFI2OzJ7NkG3
MDA-MB-231 NGXmUIRCeG:ydH;zbZMhSXO|YYm= NUXjcXd[OcLizszNxsA> MVO0PEBp M13ZfGROW09? Mn\L[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJJRz\WG2ZXSge4l1cCB{NTFOwG0hd2ZiRkGgc5IhTjJiwrC= M{\B[|I2OzByOUOy
MCF7 NEH2WnJHfW6ldHnvckBCe3OjeR?= MnLNNVAxKG6P MVuyOEBp MkLo[YxqdWmwYYTld{BGOi2rbnT1Z4VlKEGURT3MeYMh[WO2aY\peJk> NFvobVUzPTF5MkW1Oy=>
HT-29  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7r[lYyNjYEoNM1US=> MlzIPVYhcA>? NWjHVHpH\GWlcnXhd4V{KGOnbHyg[5Jwf3SqIIfobYNpKGOjbjDi[UBqdmirYnn0[YQh[nliS2nORS=> M{fLXVI2ODF{MUKz
MO59K  Mlr5R5l1d3SxeHnjbZR6KEG|c3H5 MVW1xsDPxE1? MUO3JIQ> MVTEUXNQ M3zmc4VvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= MYSyOFk2OzV4MR?=
MO59J NVrJOFJyS3m2b4TvfIlkcXS7IFHzd4F6 NGSycHo2yqEQvF2= MXq3JIQ> M{LlOWROW09? MUXlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? MVmyOFk2OzV4MR?=
MO59K  MmGyRZBweHSxc3nzJGF{e2G7 MnXVNVAh|ryP MX2yOEBp MYHEUXNQ Ml3ZbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv MUGyOFk2OzV4MR?=
MO59J NXvneJZpSXCxcITvd4l{KEG|c3H5 NILQcVAyOCEQvF2= MW[yOEBp NHzHZoVFVVOR NV;4eFdDcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NU\reYp3OjR7NUO1OlE>
HepG2 Mn\WSpVv[3Srb36gRZN{[Xl? NHn0bWIyODBibl2= M{XuWVAvPSCq NX7PTpJQTE2VTx?= MWPicI9kc3NiTVGtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;u M{njTVI1QDZ|M{Ww
A549  NXLrNFJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PhblMhyrWPwrC= MlfCNkBp MV7zeZBxemW|c3XzJJBmdWW2cnX4[YQucW6mdXPl[EBCc3RiYX7kJGdUUzQQsjDhZ5RqfmG2aX;uMEBUNXCqYYPlJIFzemW|dDygZ4VtdCCjcH;weI9{cXNiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v NFqyXVYzPDh2N{i2Ny=>
A549  NUe1VXFbTnWwY4Tpc44hSXO|YYm= M4jXfFExyqEQvH5CpC=> NUPFWpVFOTZiaB?= NID1WINFVVOR MVrtc4R2dGG2ZYOgeIhmKEmDVjDy[ZBtcWOjdHnvckBidmRiY3H1d4V{KHKndHXueIlwdiCxZjDOVEBqdiC2aHWgcpVkdGW3cz6= M{TRPVI1QDB{MUGx
SK-N-LO M33hemZ2dmO2aX;uJGF{e2G7 M1TlOVExOCCwTR?= MkixNE42KGh? MnjG[IVkemWjc3XzJJRp\SC|dHnteYxidnRiZX\m[YN1eyCxZjDtc5JxcGmwZTDvckBCc3RicHjvd5Bpd3K7bHH0bY9v NGnSRoszPDZ3NE[wOi=>
HL-60 MVLGeY5kfGmxbjDBd5NigQ>? MnjsNE4yyqEQvF2= NVH2XnpXPzJiaB?= MVnicI9kc3NiZHHzZZRqdmmkLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36= MUiyOFYxPzJ5Mx?=
HepG2  NYPufIM5TnWwY4Tpc44hSXO|YYm= MmHFNlAxKG6P M3;FdlAvPSCq MWDheJRmdnWjdHXzJGZwgE9icHjvd5Bpd3K7bHH0bY9v NWHjOWdtOjR3M{WxPVI>
H520 MkO4SpVv[3Srb36gRZN{[Xl? M3e2dVExyqEQvF2= NXXKVHd6OSCq M{jhb2ROW09? NWfaSZJl\GWlcnXhd4V{KGOnbHz1cIFzKHCqb4PwbI8uSUuWIIDyc5RmcW5ibHX2[Yx{ NHzFdpIzPDR2N{mzOS=>
H1975 MmjQSpVv[3Srb36gRZN{[Xl? NGXhfJEyOMLizszN MWWxJIg> NGLuTXlFVVOR M3\NdYRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> NIrVbGYzPDR2N{mzOS=>
MG-63 MY\BdI9xfG:|aYOgRZN{[Xl? M2O3elExKML3TR?= MV2xNkBp MXPlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MoPzNlQ{PTh|MEG=
5637 MkniRZBweHSxc3nzJGF{e2G7 MnKxNVDDqM7:TR?= NXHEZmVKPDBibXnu M4DNfpJmfmW{c3XzJJAzOVeDRkGg[ZhxemW|c3nvckwhS0SNIHX4dJJme3Orb36sJIFv\CClZXzsJIlvcGmkaYTpc44hcW6mdXPl[EBjgSCodXPvbYRidg>? MmXLNlQ{OzN6Nki=
HEK-293 MnTySpVv[3Srb36gRZN{[Xl? M3HNXlE2OG6P NELvdIIyPiCq Ml\LSG1UVw>? MWPk[YNz\WG|ZYOgR3JVKGGldHn2bZR6 MUSyOFMzPDN4Nh?=
SW480  MV3GeY5kfGmxbjDBd5NigQ>? Mk\SNVUxdk1? MoXyNlAhcA>? MXLEUXNQ MWPy[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw M2jxZ|I1OzJ2M{[2
HepG2 NYPIV|ZZTnWwY4Tpc44hSXO|YYm= NG\Rb4gyODBibl2= MmnwNlQhcA>? Mn3nZZR1\W63YYTld{B1cGViY3;sc45q\XNib3[geIhmKHS3bX;yJINmdGy|IIfpeIghfXC{ZXf1cIF1cW:wIH;mJGFsfDF? M{HCdlI1Ojl5NUGw
HCT 116  MV7GeY5kfGmxbjDBd5NigQ>? MoLkNVAxKG6P NH3tSGczPCCq NXywdIk5[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NECxUZYzPDJ7N{WxNC=>
BEL/FU MmXGSpVv[3Srb36gRZN{[Xl? NGDWRXIyKG2P M2DqV|I1KGh? Mo\K[IVkemWjc3XzJJBzd3SnaX6gcIV3\Wy|IH;mJJRp\SCSSUPLM2FsfCCyYYToe4F6 NYPL[2lrOjR{M{KwPVk>
Huh7  M{\CWGZ2dmO2aX;uJGF{e2G7 MnzCN:Kh|ryP NUDVfZJ6OSCq MWLy[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> M3:5Z|I1OTh2MUm2
A-375 Mn3RRZBweHSxc3nzJGF{e2G7 NIDDe5k1NzhizszN NXzFNGZ{OjRiaB?= NIXvU2JmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg M{jpWlI1OTF|MUez
A-375-TS  MXXBdI9xfG:|aYOgRZN{[Xl? M1rMNVQwQCEQvF2= MUOyOEBp MVzlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NVzs[o5IOjRzMUOxO|M>
Mel-HO NYHublk{SXCxcITvd4l{KEG|c3H5 M3z0VFQwQCEQvF2= NHTzT2EzPCCq NF7mUJdmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NFjiZ|YzPDFzM{G3Ny=>
Mel-HO-TS M3fEVmFxd3C2b4Ppd{BCe3OjeR?= NHjpc2k1NzhizszN NEPxdowzPCCq MkXP[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MXSyOFEyOzF5Mx?=
MeWo NYrSXlRrSXCxcITvd4l{KEG|c3H5 M4DZSlQwQCEQvF2= M4\aRlI1KGh? MV7lcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li M2LISVI1OTF|MUez
Mel-2a M{PWeWFxd3C2b4Ppd{BCe3OjeR?= NHfpOJA1NzhizszN NHPlN4IzPCCq NIr6VXVmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NHSyWZQzPDFzM{G3Ny=>
MDA-MB-231 M1e5bWZ2dmO2aX;uJGF{e2G7 NVnMXY1tOOLCk{SwNEBvVQ>? NWCzU4ZkPCCq Ml;Ld5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXHSfHp[OjJ7ME[yOVk>
MDA-MB-231 NFXhPZBHfW6ldHnvckBCe3OjeR?= MnuwOFAxKG6P NV;tclNKPCCq M{LOSoRm[3KnYYPld{BOVVBvOTDhcoQhUUxvODDwdo91\WmwIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmLkNlI6ODZ{NUm=
Jurkat NEHwOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGxNE4zPS1zLkK1JO69VQ>? NW[2TGRROjRxNEigbC=> NIHncm1FVVOR MVHpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M2jIPVE6PzV5MUi1
Namalwa NX3LUoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmwMlI2NTFwMkWg{txO MnzDNlQwPDhiaB?= MVLEUXNQ M3vKcIlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ NGfySpgyQTd3N{G4OS=>
Jurkat MlXnRZBweHSxc3nzJGF{e2G7 NHfPd3QxNjJ3LUGuNlUh|ryP MlTKNlQwPDhiaB?= NFrzN5BFVVOR MWDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= MWKxPVc2PzF6NR?=
Namalwa NGDoNHZCeG:ydH;zbZMhSXO|YYm= MlizNE4zPS1zLkK1JO69VQ>? NVjFc2VOOjRxNEigbC=> NInuVXhFVVOR MoPjbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy M1TiPVE6PzV5MUi1
K562 M4PG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOyOEBp MorDTWM2OD1{NdMxNE4yPCCwTR?= M2i0U|E6PjZ{M{[x
SW1990 NVnCV25zTnWwY4Tpc44hSXO|YYm= M1n5U|AvODFvMTFOwG0> M2LDe|EhcA>? MY\pcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NIjKXFgyQTR4OUCyNC=>
RT112  M2HwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTDW2EyOMLizszN Ml;lNlQhcA>? NWD0XnNSTE2VTx?= Mn:5[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> NXfkTVRsOTh5OEe4N|I>
MHG-U1 MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe2VZQyOMLizszN M3LiSlI1KGh? NHH0W5FFVVOR NWXnUoNz\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? MXKxPFc5Pzh|Mh?=
SMMC-7721 MU\BdI9xfG:|aYOgRZN{[Xl? MXyyNFDDqG6P NULxNIFLOjRiaB?= NVO1cXdQcW6lcnXhd4V{KEOKWD3pcoR2[2WmIHHwc5B1d3Orcx?= NFHjZ|EyPzV3N{G5NS=>
SMMC-7721 M3\vNmZ2dmO2aX;uJGF{e2G7 NHTWOFgzODEEoH7N MlvBNlQhcA>? MXX1dE1z\We3bHH0[ZMh|rJzLETHWFEh\XiycnXzd4lwdg>? MmPjNVc2PTdzOUG=
HeLa NE\TNWJHfW6ldHnvckBCe3OjeR?= NY\W[5R7OTBywrDuUeKh MmDNNUBp MVzhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= NXvh[mI2OTZ6OUC5NVU>
MRC5VI MkXnSpVv[3Srb36gRZN{[Xl? MYGxNk42KG2P NXvQOndzOC53IHi= M3j3RWROW09? MlPyZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NYf6W4xWOTZ{MkezPVQ>
AT5BIVA MUTGeY5kfGmxbjDBd5NigQ>? M1TsflEzNjVibV2= MortNE42KGh? NF3GN49FVVOR MXrhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NHv0RpYyPjJ{N{O5OC=>
M059J MkjmSpVv[3Srb36gRZN{[Xl? NXvlTllmOTJwNTDtUS=> M2jENFAvPSCq M{W4TGROW09? NF\l[pdi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MXmxOlIzPzN7NB?=
HeLa NE\E[WFHfW6ldHnvckBCe3OjeR?= NXLrV45YOTJwNTDtUS=> MoDqNE42KGh? MUHEUXNQ M4S2V4Fjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NH3pSXoyPjJ{N{O5OC=>
N2a MlPTRZBweHSxc3nzJGF{e2G7 NXy4OIdrOC5zLUGwJO69VQ>? M3TsWFIhcA>? MmfxbY5lfWOnczDk[YNz\WG|ZXSgZ4VtdCC4aXHibYxqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MUixOVg1Ojd4Nx?=
Jurkat  MXfLbY5ie2ViQYPzZZk> NVr6TXU5UUN3MDDv[kAzPCCwTR?= MVWxOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5%DMSO+corn oil 11mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID